U.S. Food and Drug Administration (OPDP / CBER Advertising and Promotional Labeling Branch) · United States

FDA Rx Promotion - Fair Balance of Benefit and Risk

Promotion must present risk information with prominence and readability reasonably comparable to the benefit claims and must not bury, shrink or visually minimize risks.

21 CFR 202.1(e)(5)(ii), (e)(7)(vii)-(viii); 21 U.S.C. 352(n)

What is FDA Rx Promotion - Fair Balance of Benefit and Risk?

Promotion must present risk information with prominence and readability reasonably comparable to the benefit claims and must not bury, shrink or visually minimize risks. Apply to prescription drug ads, web pages, emails, social posts, videos and HCP pieces that contain benefit claims and risk information.

US Federal

Read official source

Last reviewed: 2026-11-05

General information, not legal advice.

Who does this rule apply to?

general_audience, general_adults_18plus, customers, health_professionals, patients · Prescription Drug · pharma

Where does this rule apply?

United States

Which marketing channels are covered?

all_channels

When does this rule take effect?

2026-10-07

What does this rule require?

Promotion must present risk information with prominence and readability reasonably comparable to the benefit claims and must not bury, shrink or visually minimize risks.

How can marketing teams comply?

Apply to prescription drug ads, web pages, emails, social posts, videos and HCP pieces that contain benefit claims and risk information.

Where can I read the official source?

Read official source

Key facts

Regulatory authority
U.S. Food and Drug Administration (OPDP / CBER Advertising and Promotional Labeling Branch)
Jurisdiction
United States
Official citation
21 CFR 202.1(e)(5)(ii), (e)(7)(vii)-(viii); 21 U.S.C. 352(n)
Published
2026-11-16
Effective date
2026-10-07
Channel
all_channels
Products
Prescription Drug
Audiences
general_audience, general_adults_18plus, customers, health_professionals, patients

Frequently asked questions

What is FDA Rx Promotion - Fair Balance of Benefit and Risk?

Promotion must present risk information with prominence and readability reasonably comparable to the benefit claims and must not bury, shrink or visually minimize risks.

Who does this rule apply to?

general_audience, general_adults_18plus, customers, health_professionals, patients · Prescription Drug · pharma

Where does this rule apply?

United States

Which marketing channels are covered?

all_channels

When does this rule take effect?

2026-10-07

Request a free compliance scan of your homepage and book a time with Warrant.

Get a free homepage compliance scan